These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26924475)

  • 1. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Viardot A
    Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
    [No Abstract]   [Full Text] [Related]  

  • 3. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP; Colagiuri S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD
    J Diabetes Complications; 1994; 8(4):201-3. PubMed ID: 7833494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.
    Colagiuri S; Matthews D; Leiter LA; Chan SP; Sesti G; Marre M
    Diabetes Res Clin Pract; 2018 Sep; 143():1-14. PubMed ID: 29802958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B; Li YH; Chan P
    Expert Opin Pharmacother; 2022 Dec; 23(17):1869-1877. PubMed ID: 36300277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
    Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
    Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
    Rustenbeck I
    Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
    Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gliclazide modified release: its place in the therapeutic armamentarium.
    Crepaldi G; Fioretto P
    Metabolism; 2000 Oct; 49(10 Suppl 2):21-5. PubMed ID: 11078472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
    Li GW; Pan CY; Gao Y; Yuan SY; Yang WY; Xing XY; Tian H; Guo XH; Li HB
    Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
    Tsumura K
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S147-9. PubMed ID: 8529507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
    Mbanya JC; Al-Sifri S; Abdel-Rahim A; Satman I
    Diabetes Res Clin Pract; 2015 Aug; 109(2):226-32. PubMed ID: 26003888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M; Tronko M; Kravchenko V; Kovtun V
    Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.